News

Black Diamond Therapeutics: Targeted Approach And Early Efficacy Signals Create Potential For Significant Upside
Black Diamond Therapeutics's novel EGFR inhibitor shows promise in addressing resistance mutations in NSCLC and glioblastoma.
Mirage News1d
Research Reveals Trigger for EGFR Inhibitor Cytokine Storms
In a recent study, researchers have uncovered the biological trigger behind the dangerous immune-related adverse events (irAEs) that occur when the ...
PMLive1d
MHRA approves SFL’s Aumseqa to treat EGFR-mutated lung cancer in adults
The authorisation comes three months after the MHRA approved Johnson & Johnson’s Lazcluze (lazertinib), which is also ...
The Manila Times3d
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech', 6990.HK) today announced that results from its ...
Everyday Health on MSN3d
When Non-Small Cell Lung Cancer Spreads: What to Expect
What to know about new diagnostic tools, targeted medications, and other recent advances in the treatment of metastatic NSCLC ...
AlphaGalileo5d
EGFR inhibitor-linked cytokine storms: study uncovers the trigger
In a recent study, researchers have uncovered the biological trigger behind the dangerous immune-related adverse events ...
Cancer Therapy Advisor5d
Neoadjuvant Nivolumab Prolongs OS in NSCLC
Adding nivolumab to neoadjuvant chemotherapy improved OS in patients with resectable NSCLC in the CheckMate 816 trial.
Clinical Trials Arena6d
ASCO25: AbbVie flexes ADC Phase I data as NSCLC market opportunity beckons
AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...
SurvivorNet on MSN6d
Targeted Drug Tagrisso Leads To More Tumor Shrinkage For Lung Cancer Patients With EGFR Mutation: Unpacking The New Data
Patients with stage II and IIIB non-small cell lung cancer (NSCLC) with an EGFR mutation had better outcomes when treated ...
Open Access Government6d
Lung cancer drug aumolertinib approved after major trial success
The MHRA has approved aumolertinib for adult patients with non-small cell lung cancer (NSCLC), following a groundbreaking ...
Frontiers6d
EGFR-TKIs for Lung Cancer Treatment: Development, Application, and Side Effects
Lung cancer is the malignant tumor with the highest incidence and mortality rate in the world. With the in-depth research of ...